TR201722367A2 - PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL APPLICATION CONTAINING LACOSAMIDE - Google Patents

PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL APPLICATION CONTAINING LACOSAMIDE

Info

Publication number
TR201722367A2
TR201722367A2 TR2017/22367A TR201722367A TR201722367A2 TR 201722367 A2 TR201722367 A2 TR 201722367A2 TR 2017/22367 A TR2017/22367 A TR 2017/22367A TR 201722367 A TR201722367 A TR 201722367A TR 201722367 A2 TR201722367 A2 TR 201722367A2
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
lacosamide
parenteral application
application containing
containing lacosamide
Prior art date
Application number
TR2017/22367A
Other languages
Turkish (tr)
Inventor
Palantöken Arzu
Türkyilmaz Ali̇
Gülkok Yildiz
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/22367A priority Critical patent/TR201722367A2/en
Priority to EP18918418.7A priority patent/EP3731813A2/en
Priority to PCT/TR2018/050904 priority patent/WO2019240697A2/en
Publication of TR201722367A2 publication Critical patent/TR201722367A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş, lakozamid veya lakozamidin farmasötik olarak kabul edilebilir bir tuzunu içeren, indirgenmiş safsızlık ve iyileştirilmiş stabiliteye sahip intravenöz kompozisyonlarla ilgilidir.The present invention relates to intravenous compositions with reduced impurity and improved stability containing lacosamide or a pharmaceutically acceptable salt of lacosamide.

TR2017/22367A 2017-12-27 2017-12-27 PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL APPLICATION CONTAINING LACOSAMIDE TR201722367A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2017/22367A TR201722367A2 (en) 2017-12-27 2017-12-27 PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL APPLICATION CONTAINING LACOSAMIDE
EP18918418.7A EP3731813A2 (en) 2017-12-27 2018-12-26 Pharmaceutical compositions for parenteral administration comprising lacosamide
PCT/TR2018/050904 WO2019240697A2 (en) 2017-12-27 2018-12-26 Pharmaceutical compositions for parenteral administration comprising lacosamide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/22367A TR201722367A2 (en) 2017-12-27 2017-12-27 PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL APPLICATION CONTAINING LACOSAMIDE

Publications (1)

Publication Number Publication Date
TR201722367A2 true TR201722367A2 (en) 2019-07-22

Family

ID=67900901

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/22367A TR201722367A2 (en) 2017-12-27 2017-12-27 PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL APPLICATION CONTAINING LACOSAMIDE

Country Status (3)

Country Link
EP (1) EP3731813A2 (en)
TR (1) TR201722367A2 (en)
WO (1) WO2019240697A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112022804A (en) * 2020-09-28 2020-12-04 健民药业集团股份有限公司 Lacosamide oral solution and preparation method thereof
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2528891A2 (en) * 2010-01-29 2012-12-05 Ranbaxy Laboratories Limited Processes for reducing impurities in lacosamide
EP3074004A2 (en) * 2013-11-29 2016-10-05 UCB Pharma GmbH Pharmaceutical composition comprising lacosamide and levetiracetam
CN106551900A (en) * 2016-12-05 2017-04-05 北京万全德众医药生物技术有限公司 A kind of scheme for lacosamide oral administration solution and its preparation technology

Also Published As

Publication number Publication date
EP3731813A2 (en) 2020-11-04
WO2019240697A3 (en) 2020-02-13
WO2019240697A2 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
CY1120635T1 (en) AMINOETERALYL BENZAMIDS AS KINASE INhibitors
MX2018002986A (en) Heteroaryl compounds as irak inhibitors and uses thereof.
MX2017006266A (en) Heteroaryl compounds as irak inhibitors and uses thereof.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MX2018001990A (en) Compositions comprising a pi3k inhibitor and an hdac inhibitor.
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2017011655A (en) Aza-pyridone compounds and uses thereof.
EA201592268A1 (en) DIHYDROPYRIDINONE INHIBITORS MGAT2
PH12018500377A1 (en) Novel annelated benzamides
MX2017016619A (en) Pyrimidine derivatives as btk inhibitors and uses thereof.
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
SA518390920B1 (en) Novel annelated phenoxyacetamides
MX2018001517A (en) Substituted guanidine derivative.
MX2017009292A (en) (r)-2-methyl-piperazine derivatives as cxcr3 receptor modulators.
TR201901516T4 (en) Neuroprotective agents and their uses.
MY193239A (en) Novel b-lactamase inhibitors
EA201692270A1 (en) DERIVATIVES OF NAFTYRIDINDIONE
TR201722367A2 (en) PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL APPLICATION CONTAINING LACOSAMIDE
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
BR112017024126B8 (en) PHARMACEUTICAL COMPOSITIONS, MICRONIZED COMPOUND A AND/OR AT LEAST ONE MICRONIZED PHARMACEUTICALLY ACCEPTABLE SALT OF COMPOUND A AND USE THEREOF
MX2017008983A (en) Sulfonamide pharmaceutical composition.
EA201890477A1 (en) INCAPSULATED COMPOSITION OF FINGOLIMODA
IN2013MU03422A (en)
IN2014MU00859A (en)
MX2019007786A (en) Substituted guanidine compound.